II. AMENDMENT TO THE CLAIMS:

Claims 1-83 (Cancelled)

Claim 84-101 (Cancelled)

Claim 102 (Currently Amended) A method of treating Alzheimer's disease in humans, comprising

determining whether a human exhibits an elevated level of β-amyloid;

orally administering to a human patient found to exhibit an elevated level of β-amyloid ~~orally administering to a human patient found to have an APP processing disorder~~ a controlled release formulation comprising at least one HMG-CoA reductase inhibitor which after oral administration to a human patient releases said at least one HMG-CoA reductase inhibitor at a rate ~~suitable~~ to maintain therapeutically effective levels over a 24 hour dosing interval, and

continuing treatment with said controlled release formulation to effect a decrease in mean beta amyloid concentration in the blood of said human patient by at least about 18 pg/ml after 1 month of treatment.

Claim 103 (Currently amended) A method for treating Down's Syndrome in humans, comprising

orally administering to a human patient found to have Down's Syndrome a controlled release formulation comprising at least one HMG-CoA reductase inhibitor which after oral administration to a human patient releases said at least one HMG-CoA reductase inhibitor at a rate ~~suitable~~ to maintain therapeutically effective levels over a 24 hour dosing interval, and

continuing treatment with said controlled release formulation to effect a decrease in mean beta amyloid concentration in the blood of said human patient by at least about 18 pg/ml after 1 month of treatment.

Claim 104 (new) The method of claim 102, wherein therapy is continued for a minimum period of at least 90 days.

Claim 105 (new) The method of claim 102, wherein therapy is continued for a minimum period of 90 to 365 days.

Claim 106 (new) The method of claim 102, wherein said HMG-CoA reductase inhibitor is selected from the group consisting of mevastatin, pravastatin, simvastatin, atorvastatin, lovastatin, rivastatin, fluvastatin, and pharmaceutically acceptable salts, isomers, or metabolites thereof.

Claim 107 (new) The method of claim 102, wherein said HMG-CoA reductase inhibitor is lovastatin or lovastatin acid.

Claim 108 (new) The method of claim 102, wherein at least about 10 to about 60 mg of the HMG-CoA reductase inhibitor is administered per day.

Claim 109 (new) The method of claim 102, wherein said human exhibits symptoms of Alzheimer's Disease.

Claim 110 (new) The method of claim 102, further comprising preparing said controlled release formulation by combining said HMG-CoA reductase inhibitor with a pharmaceutically acceptable water swellable polymer and an osmotic agent into a compressed tablet core having at least one coating comprising a pH sensitive agent and a water insoluble polymer.

Claim 111 (new) The method of claim 110, wherein said HMG-CoA reductase inhibitor comprises from about 10 to about 60 mg lovastatin or a pharmaceutically acceptable salt thereof.

Claim 112 (new) The method of claim 110, wherein said HMG-CoA reductase inhibitor comprises lovastatin acid.

Claim 113 (new) The method of claim 110, wherein said formulation further comprises a seal coating applied to the compressed tablet.

Claim 114 (new) The method of claim 110, wherein said formulation further comprises a coating layer comprising an enteric coating agent.